The most commonly mutated genes in the whole cohort were NPM1 (32%), TET2 (28%), and DNMT3A (25%) (Fig. 1a, Supplementary Table S2), while the most common mutations in patients with de novo AML were NPM1 (37%), DNMT3A (28%), and FLT3-ITD (26%). This evidence concerns the gene TET2 and acute myeloid leukemia.